FDA brings GSK's Blenrep back to the market in multiple myeloma
FDA将GSK的Blenrep带回多发性骨髓瘤市场

The FDA has approved GSK’s Blenrep as a third-line multiple myeloma drug, overcoming a negative advisory committee vote and clearing the way for a relaunch in the US.
美国食品药品监督管理局(FDA)已批准GSK的Blenrep作为三线多发性骨髓瘤药物，推翻了顾问委员会的否定投票，为其在美国的重新上市扫清了道路。